sargramostim 0.25 MG/ML Injectable Solution [Leukine]

What the CMS Formulary Data Shows for sargramostim 0.25 MG/ML Injectable Solution [Leukine]

Per the CMS 2026 Part D formulary file, sargramostim 0.25 MG/ML Injectable Solution [Leukine] (RxNorm concept RXCUI 208083, generic name sargramostim) appears on 58 distinct formulary files spanning 473 Medicare Part D plan offerings - 9.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.1.

Real-world access to sargramostim 0.25 MG/ML Injectable Solution [Leukine] depends on utilization management as much as tier placement: 74.1% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 113 Part D beneficiaries filled sargramostim 0.25 MG/ML Injectable Solution [Leukine] in 2023, with total plan-and-beneficiary spending of $3,139,334 and an average per-beneficiary annual cost of $27,781.71. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry sargramostim 0.25 MG/ML Injectable Solution [Leukine] today.